Study Evaluating Nivolumab (Anti-PD-1 Antibody) Alone Versus Nivolumab Plus Ipilimumab (Anti-CTLA-4 Antibody) in Patients With Resectable and Potentially Resectable Hepatocellular Carcinoma (HCC) (CA209-956)

Conditions:   Malignant Neoplasms of Digestive Organs;   Hepatocellular Carcinoma Interventions:   Drug: Nivolumab;   Drug: Ipilimumab Sponsors:   M.D. Anderson Cancer Center;   Bristol-Myers Squibb Not yet recruiting - verified July 2017 (Source: ClinicalTrials.gov)

from ! Medicine by Alexandros G. Sfakianakis via alwin on Inoreader https://medworm.com/377829718/study-evaluating-nivolumab-anti-pd-1-antibody-alone-versus-nivolumab-plus-ipilimumab-anti-ctla-4-/
via IFTTT